Compare VanEck Junior Gold Miners (GDXJ) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Twist Bioscience Corp — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is the larger of the two by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, VanEck Junior Gold Miners nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Twist Bioscience Corp for 27 Days on average.
| GDXJ | TWST | |
|---|---|---|
Market Cap | $8.22B | $10.08B |
Volume | 3,212,198 | 4,229,037 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $205.00 |
52-Week Low | $87.56 | $25.45 |
Typical Hold Time | 41 Days | 27 Days |
Enterprise Value | — | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $110.91, up 1.62% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Recent news highlights multiple junior gold mining companies being added to the ETF, potentially increasing its diversification and appeal. Key financial ratios are not applicable as this is an ETF tracking an index of companies.
The outlook for GDXJ is influenced by gold price volatility and the performance of its underlying junior mining holdings. Opportunities exist if gold prices rise, boosting miner profitability, but risks include operational challenges and market sentiment shifts. Investors should weigh exposure to small-cap miners against broader market conditions.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
